Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Articles

Pages

1782 items
1:30 PM, Oct 12, 2018  |  BioCentury | Emerging Company Profile

Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies. Antibodies can act on their targets with better...
11:32 AM, Sep 28, 2018  |  BioCentury | Emerging Company Profile

Stopping chain swapping

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies. The company develops multispecific antibodies with up to four functional domains that bind...
3:29 PM, Sep 21, 2018  |  BioCentury | Emerging Company Profile

Aprinoia tackles tau

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to develop...
12:44 PM, Sep 14, 2018  |  BioCentury | Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
11:46 AM, Sep 07, 2018  |  BioCentury | Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and CEO...
4:41 PM, Aug 03, 2018  |  BioCentury | Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
12:11 PM, Jul 27, 2018  |  BioCentury | Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...
1:26 PM, Jul 20, 2018  |  BioCentury | Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
1:03 PM, Jul 06, 2018  |  BioCentury | Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic drugs...
5:55 PM, Jun 22, 2018  |  BioCentury | Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...

Pages